<DOC>
	<DOCNO>NCT01500122</DOCNO>
	<brief_summary>The primary objective study : - To compare pharmacokinetic profile RhuDex administer two novel oral formulation - To identify lead formulation optimise pharmacokinetic profile modify quantitative composition formulation - Optional : To assess intravenous pharmacokinetics RhuDex follow administration IV microtracer [ 14C ] RhuDex</brief_summary>
	<brief_title>Study Evaluating Pharmacokinetic Profile Novel Formulations RHUDEX®</brief_title>
	<detailed_description />
	<criteria>1 . Healthy male ; 2 . Age 1845 year ; 3 . Body weight 7080 kg ; 4 . Body Mass Index ( BMI ) 1825 kg/m2 ; 5 . Subject must agree use adequate method contraception ( defined section 9.4 ) ; 6 . Must provide write informed consent ; 7 . Nonsmokers ( subject never smoke ) ; 8 . Absence cardiovascular risk factor screen include 12lead standard ECG , acceptable clinical laboratory test follow laboratory parameter within acceptable range : CK ; LDH ; GPT/GOT ( ALAT/ASAT ) ; yGT , total vs. unconjugated/conjugated serum bilirubin ; serum creatinine judge Investigator 9 . Must willing able communicate participate whole study . 1 . Participation clinical research study within previous 3 month ; 2 . Subjects previously enrol study ; 3 . History drug alcohol abuse past 2 year ; 4 . Regular alcohol consumption male &gt; 21 unit per week ( 1 unit = ½ pint beer , 25 mL 40 % spirit 125 mL glass wine ) ; 5 . A breath carbon monoxide read great 10 ppm screening ; 6 . Radiation exposure clinical study , include present study , exclude background radiation include diagnostic Xrays medical exposure , exceed 5 mSv last twelve month 10 mSv last five year . No occupationally expose worker , define Ionising Radiation Regulations 1999 , shall participate study ; 7 . Clinically significant abnormal biochemistry , haematology urinalysis judge Investigator ( Section 20 ) ; 8 . Positive drug abuse test result ( Section 20 ) ; 9 . Positive HBV , HCV HIV result ; 10 . History cardiovascular disease , 11 . History sudden death cardiovascular death age 50 first degree relative ; 12 . History clinically significant renal , hepatic , respiratory particularly gastrointestinal disease , especially peptic ulceration , gastrointestinal bleeding , ulcerative colitis , Crohn 's Disease Irritable Bowel Syndrome ; 13 . Any chronic infection e.g . TB 14 . Serious adverse reaction serious hypersensitivity drug formulation excipients ; 15 . Presence history allergy require treatment . Hayfever allow unless active ; 16 . Donation loss great 400 mL blood within previous three month ; 17 . Subjects receive prohibited medication describe Section 9.5 ; 18 . Subjects receive follow medication regular basis within previous 3 month : antihypertensives ßblockers , Cachannelinhibitors inhibitor reninangiotensinsystem , statin , ASS NSAIDs , diuretic , antacids/PPIs ; anticoagulant , antiarrhythmic , antidepressant , antipsychotic ; 19 . Failure satisfy Investigator fitness participate reason .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>